Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Share-based Compensation (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Share-based Compensation for 16 consecutive years, with $172160.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 130.12% to $172160.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $408320.0 through Dec 2025, up 35.25% year-over-year, with the annual reading at $408320.0 for FY2025, 35.25% up from the prior year.
  • Share-based Compensation hit $172160.0 in Q4 2025 for Cumberland Pharmaceuticals, up from $81262.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $224786.0 in Q4 2021 to a low of -$27753.0 in Q2 2022.
  • Historically, Share-based Compensation has averaged $113231.2 across 5 years, with a median of $92025.0 in 2023.
  • Biggest five-year swings in Share-based Compensation: tumbled 114.46% in 2022 and later soared 452.68% in 2023.
  • Year by year, Share-based Compensation stood at $224786.0 in 2021, then tumbled by 43.54% to $126905.0 in 2022, then decreased by 26.01% to $93894.0 in 2023, then fell by 20.32% to $74812.0 in 2024, then skyrocketed by 130.12% to $172160.0 in 2025.
  • Business Quant data shows Share-based Compensation for CPIX at $172160.0 in Q4 2025, $81262.0 in Q3 2025, and $80686.0 in Q2 2025.